AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca, in collaboration with Parexel International, has recently completed a clinical study titled An Open-label, Randomised, 2-arm, 3-period, 6-treatment Single-dose, Crossover Study Comparing the Pharmacokinetics of 2 Different Formulations of AZD4144, and Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants. The study aimed to evaluate the pharmacokinetics of two formulations of AZD4144 and the impact of food and omeprazole on its absorption in healthy individuals, providing valuable insights into the drug’s potential efficacy and safety.
The study tested two formulations of AZD4144, a drug administered orally, and examined its interaction with omeprazole, a common medication used to reduce stomach acid. The goal was to understand how these formulations behave under different conditions, such as fasting and fed states, and when combined with omeprazole.
This Phase I study was designed as an open-label, randomized, single-dose, crossover trial. Participants were randomly assigned to different treatment sequences, receiving various combinations of AZD4144 and omeprazole. The primary purpose was to assess treatment effects, with no masking involved.
The study began on April 23, 2025, and was completed by July 22, 2025. These dates are crucial as they mark the timeline for data collection and analysis, which can influence the drug’s development and regulatory approval process.
The completion of this study could have significant implications for AstraZeneca’s stock performance, as positive results may enhance investor confidence and market competitiveness. The pharmaceutical industry closely monitors such developments, as they can shift market dynamics and impact competitor strategies.
The study is now completed, and further details can be accessed on the ClinicalTrials portal.